European Heart Journal

European Heart Journal Advance Access originally published online on April 13, 2006
European Heart Journal 2006 27(12):1423-1430; doi:10.1093/eurheartj/ehi885

This Article Abstract Full Text (PDF) All Versions of this Article: 27/12/1423    most recent ehi885v2 ehi885v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in EHJ Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (9) Request Permissions Google Scholar Articles by Zhang, Q. Articles by Yu, C.-M. Search for Related Content PubMed PubMed Citation Articles by Zhang, Q. Articles by Yu, C.-M. Social Bookmarking          What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure

Qing Zhang¹, Jeffrey Wing-Hong Fung¹, Angelo Auricchio², Joseph Yat-Sun Chan¹, Leo C.C. Kum¹, Li Wen Wu¹ and Cheuk-Man Yu^1,*

¹ Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, S.H. Ho Cardiovascular and Stroke Centre, Institute of Vascular Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong
² Fondazione Cardiocentro Ticino, Via Tesserete 48, CH-6900 Lugano, Switzerland

Received 16 December 2005; revised 14 March 2006; accepted 23 March 2006; online publish-ahead-of-print 13 April 2006.

^* Corresponding author. Tel: +852 2632 3594; fax: +852 2637 5643. E-mail address: cmyu{at}cuhk.edu.hk

See page 1392 for the editorial comment on this article (doi:10.1093/eurheartj/ehl048)

	Abstract

Top Abstract Introduction Methods Results Discussion Conclusion Acknowledgement References

 
Aims LV reverse remodelling has been shown to be a favourable response after cardiac resynchronization therapy (CRT) in many clinical trials. This study investigated whether left ventricular (LV) reverse remodelling after CRT has any structural benefit, which include the improvement of LV mass or regional wall thickness.

Methods and results Fifty patients (66±11 years) receiving CRT were followed up for at least 3 months. Echocardiography with tissue Doppler imaging was performed serially before and at day 1 and 3 months after CRT. Although LV end-systolic volume (LVESV) was decreased at day 1 after CRT (141±74 vs. 129±71 cm³, P<0.001), further LV reverse remodelling was observed at 3 months (110±67 cm³, P<0.001 vs. day 1). LV ejection fraction increased at day 1 (26.5±9.3 vs. 28.5±9.1%, P<0.005) and was further improved at 3 months (34.2±10.5%, P<0.001 vs. day 1). However, reduction of LV mass (231±67 vs. 213±59 g, P<0.001) and regional wall thickness was only observed at 3 months, but not at day 1. The improvement of LV mass correlated with the change in LVESV (r=0.66, P<0.001) and the baseline systolic asynchrony index (Ts-SD) (r=–0.52, P<0.001). LV mass was only decreased significantly in responders of LV reverse remodelling (245±66 vs. 207±61 g, P<0.001), but increased in non-responders (209±64 vs. 223±56 g, P=0.02). Responders had significant decrease in thickness of all the four walls for –6 to –11% (all P0.02), whereas non-responders had increased thickness in septal and lateral walls for +11% (both P<0.05).

Conclusion The acute reduction in LV volume after CRT is mediated by haemodynamic and geometric benefits without actual changes in LV mass. However, at 3-month follow-up, reduction in LV mass and regional wall thickness was demonstrated, which represents structural reverse remodelling. Such benefit was only observed in volumetric responders but was worsened in non-responders.

Key Words: Cardiac resynchronization therapy • Left ventricular mass • Reverse remodelling • Echocardiography

	Introduction

Top Abstract Introduction Methods Results Discussion Conclusion Acknowledgement References

 
Cardiac resynchronization therapy (CRT) has become an established treatment for patients with advanced chronic heart failure and prolonged QRS complexes.^1–4 Clinical data have confirmed the benefits of CRT on symptoms, exercise capacity, quality-of-life, left ventricular (LV) reverse remodelling, and long-term prognosis including mortality and heart failure hospitalization.^1–6 In fact, LV reverse remodelling detected by echocardiography or other non-invasive methods is an objective endpoint, which is thought to contribute to the symptomatic benefits of CRT⁷ and may herald the improvement of long-term survival.^5,6,8–10 Recently, a 10% reduction of LV end-systolic volume (LVESV) after CRT for 3 to 6 months is found to be associated with a significantly lower all-cause mortality and heart failure events.⁵ Therefore, LV reverse remodelling has recently been adopted as an endpoint measure to signify functional improvement of LV in multicentre trials of CRT.¹¹ Our previous studies observed that a small but significant degree of reduction in LV volume and gain in EF was obtained even after CRT for less than 48 h.¹² Apart from this functional and geometrical improvement, the MIRACLE study also reported reduction of LV mass from 3 to 6 months after CRT,⁶ whereas other studies found no evidence of such changes. The study of LV mass by M-mode echocardiography is limited by the over-simplified nature of measurement, in particular it is invalid in the population with regional asynchrony.^13,14 In order to confirm any structural change in the LV and calculate the LV mass more precisely, the use of careful method based on two-dimensional echocardiography is helpful, which will provide information on both global and regional changes in LV. This study examined whether chronic LV reverse remodelling is contributed by a reduction of LV mass apart from haemodynamic and geometric benefits after the therapy and determined whether there is any difference in structural remodelling between volumetric responders and non-responders.

	Methods

Top Abstract Introduction Methods Results Discussion Conclusion Acknowledgement References

 
Patients
The study population consisted of 50 patients (66±11 years) with advanced congestive heart failure, who had received CRT and followed up for at least 3 months. The inclusion criteria of CRT included symptomatic heart failure despite optimal pharmacological therapy, New York Heart Association (NYHA) class III or IV heart failure, evidence of LV systolic dysfunction with an EF <40%, and QRS duration >120 ms in the form of bundle branch block or intraventricular conduction delay. The demographic and clinical characteristics of the patients are shown in Table 1. Serial standard echocardiography with tissue Doppler imaging (TDI) was performed at baseline, day 1, and 3 months after CRT. Clinical assessment was also performed at baseline and 3 months after CRT. The study protocol was approved by the Ethics Committee, and the written informed consent was obtained from each participant.

View this table: [in this window] [in a new window]   Table 1 Baseline demographic and clinical characteristics of the study population

 
Biventricular device implantation
Biventricular devices were implanted as previously described.^4,7 The LV pacing lead was inserted by a transvenous approach through the coronary sinus into either the lateral or postero-lateral cardiac vein in all but five patients. It was placed in the antero-lateral vein in three patients and in the anterior cardiac vein in another two patients. Thirty-seven patients received an Attain system [Model 2187, Model 4189, Model 4191 (side-wire lead), or Model 4193 (over-the-wire lead)] (Medtronic Inc., Minneapolis, MN, USA) and 13 received the Easytrak over-the-wire lead (Model 4512, Guidant Inc., St Paul, MN, USA). Only three patients had CRT+defibrillator devices (InSync ICD or Contak CD), whereas all the others received biventricular pacemakers (InSync, InSync III, Contak TR, or Contak TR II).

Echocardiography
Echocardiography with TDI was performed (Vivid 5 or Vivid 7, Vingmed-General Electric, Horten, Norway) serially before CRT, day 1 after implantation, and 3 months after CRT. The atrioventricular interval was optimized by Ritter's method at day 1 after implantation to reach maximal transmitral diastolic filling.¹⁵ The LV volumes and EF were assessed by biplane Simpson's equation using the apical four-chamber and two-chamber views, where the length of the ventricular image was maximized. The LV mass was measured by the two-dimensional method using area-length formula as previously described.¹⁶ The mid-ventricular short-axis view at the level of papillary muscle tips at end-diastolic frame was used for tracing the epicardial and cavity areas. In the same view, LV regional wall thickness was measured at the 3, 6, 9, and 12 O'clock positions which represent lateral, inferior, septal, and anterior walls, respectively. The intra- and inter-observer variabilities for volumetric analysis were 4 and 5%, respectively.⁷ The LV mass assessment was performed by one observer who was blinded to the other measurements. Cardiac output, LV sphericity indices, rate of pressure rise in systole (+dp/dt), and mitral regurgitation were measured as previously described.^7,17,18

Two-dimensional colour TDI was performed using apical views (apical four-chamber, two-chamber, and long-axis views) for the long-axis motion of the ventricles as previously described.^7,19,20 At least three consecutive beats were stored, and the images were analysed offline by a customized software package (EchoPac PC, Vingmed-General Electric, Horten, Norway). Myocardial velocity curves were reconstituted offline using the 6-basal, 6-mid segmental model in the LV as previously described.^7,20,21 Regional peak myocardial systolic velocity during ejection phase (Sm) and the time to the peak systolic velocity during ejection phase (Ts) were measured in each segment.^7,22–24 Parameters of systolic asynchrony were measured, which included systolic asynchrony index (Ts-SD, i.e. the standard deviation of Ts among the 12 LV segments), the maximal difference in Ts between any two out of the 12 LV segments (Ts-12-dif), and the absolute difference in Ts between the basal septal and basal lateral segments (Ts-sept-lat).^7,21

Statistical analyses
For comparison of parametric variables between different time-points, i.e. baseline, day 1, and 3 months after CRT, paired sample t-test with Bonferroni correction was used. The comparison of continuous clinical and echocardiographic parameters between volumetric responders and non-responders was performed by unpaired t-test. Correlation analysis was used to compare the relationship between parameters of systolic asynchrony and the change of LV mass or wall thickness in a univariate model. All parametric data were expressed as mean±SD. A P-value <0.05 was considered statistically significant where two-sided test was used.

	Results

Top Abstract Introduction Methods Results Discussion Conclusion Acknowledgement References

 
Changes in LV volume, LV mass, LV regional wall thickness, and clinical parameters after CRT
On the first day after CRT, the optimal atrioventricular interval was 101±27 ms. The LV end-diastolic volume (LVEDV) (P<0.001) and LVESV (P<0.001) were significantly reduced with gain in ejection fraction (EF) (P=0.005). The LV end-systolic sphericity index was increased (P=0.006). However, there was no significant change in LV mass (P=0.493). The LV mid-wall thickness in the four regions was also unchanged (Table 2 and Figure 1). Other echocardiographic parameters of cardiac function were improved, which included mitral regurgitation (P<0.001) and +dp/dt (P=0.030). There was a trend but insignificant increase in cardiac output (Table 2).

View this table: [in this window] [in a new window]   Table 2 Comparison of clinical parameters, LV volume, mass, and other echocardiographic parameters of cardiac function at baseline, day 1, and 3 months after CRT

 

View larger version (9K): [in this window] [in a new window]   Figure 1 Changes in (A) LVEDV and LVESV. *P<0.001  vs. baseline. P<0.005  vs. day 1. P<0.001  vs. day 1. (B) LV mass over the time after CRT. *P<0.001  vs. baseline. P<0.001  vs. day 1.

 
At the end of 3 months after CRT, there was an obvious LV reverse remodelling response as reflected by further reduction in LVEDV (P<0.001 vs. baseline, P=0.003 vs. day 1) and LVESV (P<0.001 vs. baseline, P<0.001 vs. day 1). The LVEF was further increased (P<0.001 vs. baseline, P<0.001 vs. day 1). The sphericity index at end-diastole (P=0.039 vs. baseline) and end-systole (P=0.004 vs. baseline) were improved. Moreover, the LV mass was significantly reduced (P<0.001 vs. baseline). Reduction of LV mid-wall thickness was observed in the anterior wall when compared with baseline (P=0.036) (Table 2 and Figure 1). Interestingly, the septal/lateral wall thicknesses were significantly greater than that of the anterior/inferior wall, for both baseline and after CRT for 3 months (Table 2). For other echocardiographic parameters of cardiac function, they were improved at 3 months, namely +dp/dt (P=0.002), cardiac output (P=0.039), and mitral regurgitation (P<0.001), when compared with baseline (Table 2). Clinical assessment showed significant improvement of NYHA class, quality-of-life, and 6 min hall walk distance after CRT for 3 months (all P<0.001).

LV mass, LV regional wall thickness, and its relationship with LV reverse remodelling response
Successful LV reverse remodelling was defined by a reduction of LVESV 10% at 3 months after CRT when compared with baseline.⁵ By this criterion, 30 (60%) patients were labelled as volumetric responders, whereas 20 patients were non-responders in whom the reduction of LVESV was <10%. These two groups have comparable baseline echocardiographic characteristics with similar LV volume, LV mass, and systolic and diastolic functions (Table 3). In contrast, the changes in cardiac mass and function were very different between the two groups.

View this table: [in this window] [in a new window]   Table 3 Comparison of clinical parameter, LV volume, mass, and other echocardiographic parameters of cardiac function according to status of response to CRT

 
In the responders of LV reverse remodelling, there was significant decrease in LV mass (P<0.001) and increase in both end-diastolic (P<0.001) and end-systolic (P<0.001) sphericity index. The LVEF (P<0.001) was increased. The myocardial performance index was improved (P=0.01). The LV mid-wall thickness was significantly decreased in all the regions studied, namely septal (P<0.001), lateral (P=0.02), anterior (P<0.001), and inferior walls (P=0.006) (Table 3).

On the contrary, non-responders of LV reverse remodelling had significant increase in LV mass (P=0.02). The sphericity index was significantly worsened, indicating a more globular shaped heart (P=0.02). Furthermore, the LV regional wall thickness not only showed no improvement but was further increased in both the septal (P=0.04) and lateral (P=0.03) walls (Table 3).

In fact, when the magnitude of changes in LV mass and other echocardiographic parameters were compared, there was a significant difference between responders and non-responders (–15±13 vs. +9±13%, P<0.001). The parameters for LV reverse remodelling were highly different between the two groups, namely LV volumes, EF, and sphericity indices (all P<0.001) (Figure 2A). Similarly, when the percentage change in regional wall thickness was compared, it was observed to change in an opposite manner in all the four regions. Responders had a significant decrease in thickness of all the four walls for –6 to –11%, whereas non-responders had a significant increase for +11% in septal and lateral walls (both P0.001 vs. responders), and increase for +9% in anterior (P<0.001 vs. responders) and inferior walls (P=0.002 vs. responders) (Figure 2B).

View larger version (12K): [in this window] [in a new window]   Figure 2 Changes of parameters of LV reverse remodelling between responders and non-responders in percentage. (A) LVEDV, LVESV, EF, end-diastolic sphericity index, end-systolic sphericity index, LV mass, and *P<0.001 vs. responders; (B) wall thickness in the four sites, namely anterior, inferior, septal, and lateral mid-LV wall, *P<0.001 vs. responders, P=0.002 vs. responders, P=0.001 vs. responders.

 
When the degree of LV reverse remodelling and improvement of LV mass and thickness were compared, a close correlation between the change in LVESV and change in LV mass was observed (r=0.66, P<0.001) (Figure 3). For individual wall, the change in septal wall thickness correlated more with the change in LVESV (r=0.45, P=0.001), which was followed by anterior (r=0.35, P=0.010) and lateral (r=0.32, P=0.020) walls, but not the inferior wall (r=0.21, P=0.146).

View larger version (8K): [in this window] [in a new window]   Figure 3 A scatter plot of the change in LVESV and the change in LV mass at the end of 3 months after CRT.

 
The percentage change in LV mass, regional wall thickness, and reverse remodelling was attempted to compare between non-ischaemic (n=26) and ischaemic (n=24) patients. However, though the non-ischaemic group appeared to have a better response, none of the parameters showed a significant difference, namely LV mass (–8.4±18.5 vs. –2.9±16.2%, P=0.265), anterior wall (–1.8±18.9 vs. –3.9±18.3%, P=0.696), inferior wall (–2.1±20.2 vs. +1.5±16.9%, P=0.497), septal wall (–5.5±18.1 vs. +4.4±20.0%, P=0.072), and lateral wall (–2.2±18.2 vs. +4.5±17.1%, P=0.181) thickness, LVEDV (–17.5±18.9 vs. –10.5±19.2%, P=0.196), LVESV (–25.2±23.2 vs. –17.7±23.5%, P=0.264), and LVEF (+47.8±54.9 vs. +25.6±30.1%, P=0.087). Moreover, the response rates of reverse remodelling in non-ischaemic and ischaemic patients were similar (57.5 vs. 62.5%, P=0.729).

Relationship between change in systolic asynchrony, regional systolic function, and LV mass
Systolic asynchrony index at baseline was significantly larger in responders than in non-responders of LV reverse remodelling (P<0.001). An improvement of asynchrony index after CRT was observed in the responders (P=0.001) but was further worsened in the non-responders (P=0.020). Similar observation was observed in other parameters of systolic asynchrony, namely Ts-12-diff and Ts-sept-lat (Table 4). There was a significant correlation between the severity of baseline systolic asynchrony and the degree of reduction of LV mass after CRT for 3 months. Such relationship was the strongest for asynchrony index (r=–0.52, P<0.001) (Figure 4), which was followed by Ts-12-diff (r=–0.49, P<0.001), and was the least for Ts-sept-lat (r=–0.34, P=0.020).

View this table: [in this window] [in a new window]   Table 4 Comparison of LV asynchrony and regional peak myocardial velocity by TDI according to the status of response to CRT

 

View larger version (8K): [in this window] [in a new window]   Figure 4 A scatter plot of the baseline systolic asynchrony index as measured by the standard deviation of the time to peak myocardial systolic velocity of the 12 LV segments (Ts-SD) and the change in LV mass at the end of 3 months after CRT.

 
Regional peak myocardial systolic velocity (Sm) was also studied by TDI (Table 4). In the responders, the Sm had a significant improvement in the septal (P<0.001) and inferior (P=0.004) walls and a trend but insignificant increase in the anterior and lateral walls. In contrast, the Sm was unchanged in all the four walls in the non-responders.

	Discussion

Top Abstract Introduction Methods Results Discussion Conclusion Acknowledgement References

 
This study provides some new insights about improvement of LV volumes and cardiac function after CRT, which is very different between immediately after device implantation and chronic follow-up. Within 24 h after CRT, there was acute, but a small extent, reduction in LV volume and gain in EF; without changes in LV mass or regional wall thickness. However, there was structural remodelling of the LV and regression of wall thickness upon 3-month follow-up, which was associated with greater magnitude of reduction in LV volume and increase in EF. Of note, the favourable structural and functional reverse remodelling of the LV with regression of global and regional LV mass only occurred in those volumetric responders but was worsened in the non-responders, indicating disease progression.

Evidence of LV structural reverse remodelling with reduction in LV mass
Chronic LV reverse remodelling response after CRT has been observed consistently in previous studies, which is associated with a better prognosis, including a lower mortality as well as fewer heart failure hospitalizations.^2,5–9 It is likely combined effects of improvement in intraventricular synchronicity,⁷ haemodynamics,^17,25 atrioventricular synchronicity,²⁶ interventricular synchronicity,^7,9 and mitral regurgitation.^7,9 A small amplitude of reduction in LV volume and increase in EF was observed within the first 24 h after CRT in an early study,¹¹ as well as in the present study. However, the key information is that the LV mass and regional wall thickness in all the LV sites were unchanged in the acute stage. Therefore, such acute benefit is explained by the haemodynamic effect as a result of pressure and volume unloading through improvement of systolic asynchrony and reduction of mitral regurgitation.⁷ However, cardiac remodelling is a process that involves structural changes in the LV resulting in cardiac dilatation, progressive loss of cardiac function, and hypertrophy. In order to prove the true benefit of LV reverse remodelling, it has been suggested that a decrease in LV mass has to be demonstrated. The MIRACLE study reported a reduction of LV mass for 12 g in the CRT treatment group at the medium-term, which was significant when compared with an increase for 10 g in the CRT-off group. However, it is not clear whether the 3–4% of reduction itself in the CRT group or the increase in the control group was significant. The current study measured LV mass using a more comprehensive method which showed a highly significant reduction of nearly 8% after CRT in the whole study population. This benefit is present globally throughout the whole LV, as mid-wall thickness in all the four measured regions was significantly reduced. A close correlation was found between the degree of reverse remodelling and reduction in LV mass. Therefore, the decrease in LV mass that occurred over 3 months of treatment is probably due to a decrease in both wall thickness and overall chamber size. This is compatible with the previous observation that the maximal benefits of CRT take time to maximize.⁷ The occurrence of LV reverse remodelling will further decrease the metabolic demand by lowering the global and regional wall stress.^27,28 This will form a positive feedback that favours further regression of LV hypertrophy.

Differential changes in LV mass between responders and non-responders
Despite the consistent benefits of CRT, the lack of reverse remodelling response occurs in more than one-third of patients.^17,22 In previous studies, a reduction in LVESV is associated with a more favourable prognosis in multicentre pharmacological trials of heart failure.^29–31 The current study adopted a 10% cutoff value of LVESV to signify reverse remodelling, as volumetric responders above this threshold has been shown to predict a better long-term prognosis.⁵ Interestingly, only responders had a significant decrease in LV mass for a mean amplitude of over 15% and reduction of wall thickness in all the regions which ranged from 7 to 11%. In contrast, non-responders behaved in the opposite direction with increase in LV mass and regional wall thickness. With respect to the aetiology of heart failure, the present study did not demonstrate any difference in the extent of improvement in LV mass or other parameters of reverse remodelling between ischaemic and non-ischaemic patients after CRT.

It is interesting to note that the increased regional wall thickness is particular serious over the septal and lateral walls at baseline in both groups. Furthermore, the worsening of wall thickness was particularly severe over these regions in the non-responders. In studies of electrical mapping for patients with prolonged QRS duration, septal depolarization is always early, whereas the functional conduction block at the anterior or posterior walls will render a delay in the lateral wall region.^32,33 Therefore, the hyperactive septal contraction during early systole probably exerts extra stress on the relatively relaxed orthogonal lateral wall. Subsequently, the early relaxed septum will have extra wall stress during late systole and even isovolumic relaxation period when the lateral wall contraction is delayed. As a result, the septal and lateral walls are often subjected to greater wall stress than the anterior and inferior walls and therefore more severe hypertrophy. In fact, improvement of septal wall function was evident by TDI in the responders after abolishment of asynchrony and paradoxical septal motion.

In the present study, a significant correlation was demonstrated between the baseline systolic asynchrony and the reduction of LV mass. As the responders had larger values of asynchrony index than the non-responders and the severity of pre-pacing asynchrony also shown correlated with the reduction of LVESV, it appears that pre-pacing asynchrony is an important determinant of both structural and functional reverse remodelling. As similar to LV mass, systolic asynchrony index was decreased in responders but increased in non-responders. Therefore, CRT reverses systolic asynchrony, which leads to the favourable change in LV wall thickness and LV volume.

	Conclusion

Top Abstract Introduction Methods Results Discussion Conclusion Acknowledgement References

 
The reduction of LV mass and wall thickness are important and objective markers of LV structural reverse remodelling after CRT. Such structural benefit was not present immediately after device implantation but occurred gradually after 3 months, though it was only observed in volumetric responders. On the contrary, increase in LV mass and septal/lateral wall thickness was observed in non-responders. Therefore, this study provides some new insights into LV reverse remodelling, supporting chronic structural regression of LV mass on top of haemodynamic benefit.

	Acknowledgement

Top Abstract Introduction Methods Results Discussion Conclusion Acknowledgement References

 
This study was supported by a research grant from Li Ka Shing Institute of Health Sciences.

Conflict of interest: none declared.

	References

Top Abstract Introduction Methods Results Discussion Conclusion Acknowledgement References

 

1. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150.[Abstract/Free Full Text]
2. Abraham WT, Fisher WG, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845–1853.[Abstract/Free Full Text]
3. Gras D, Leclercq C, Tang AS, Bucknall C, Luttikhuis HO, Kirstein-Pedersen A. (2002) Cardiac resynchronization therapy in advanced heart failure-the multicenter InSync clinical study. Eur J Heart Fail 4:311–320.[CrossRef][ISI][Medline]
4. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC. (2001) Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344:873–880.[Abstract/Free Full Text]
5. Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE, Chan YS, Kong SL, Bax JJ. (2005) Left ventricular reverse remodelling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 112:1580–1586.[Abstract/Free Full Text]
6. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1594–1597.[Free Full Text]
7. Yu CM, Chau E, Sanderson JE, Fan K, Tang MO, Fung WH, Lin H, Kong SL, Lam YM, Hill MR, Lau CP. (2002) Tissue Doppler echocardiographic evidence of reverse remodelling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 105:438–445.[Abstract/Free Full Text]
8. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Fisher WG, Ellestad M, Messenger J, Kruger K, Hilpisch KE, Hill MR. (2003) Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107:1985–1990.[Abstract/Free Full Text]
9. Salukhe TV, Francis DP, Sutton R. (2003) Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitalization. Int J Cardiol 87:119–120.[CrossRef][ISI][Medline]
10. Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN, Kass DA, Powe NR. (2003) Cardiac Resynchronization and Death From Progressive Heart Failure: A Meta-analysis of Randomized Controlled Trials. JAMA 289:730–740.[Abstract/Free Full Text]
11. Yu CM, Abraham WT, Bax J, Chung E, Fedewa M, Ghio S, Leclercq C, Leon AR, Merlino J, Nihoyannopoulos P, Notabartolo D, Sun JP, Tavazzi L, PROSPECT Investigators. (2005) Predictors of response to cardiac resynchronization therapy (PROSPECT)–study design. Am Heart J 149:600–605.[CrossRef][ISI][Medline]
12. Yu CM, Lin H, Fung WH, Zhang Q, Kong SL, Sanderson JE. (2003) Comparison of acute changes in left ventricular volume, systolic and diastolic functions, and intraventricular synchronicity after biventricular and right ventricular pacing for heart failure. Am Heart J 145:846.[CrossRef]
13. Ricci R, Ansalone G, Toscano S. (2000) Cardiac resynchronization: materials, technique and results. The InSync Italian Registry 2:Suppl. J, J6–J15.
14. Saxon LA, De Marco T, Schafer J, Chatterjee K, Kumar UN, Foster E, VIGOR Congestive Heart Failure Investigators. (2002) Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodelling. Circulation 105:1304–1310.[Abstract/Free Full Text]
15. Ritter P, Padeletti L, Gillio-Meina L, Gaggini G. (1999) Determination of the optimal atrioventricular delay in DDD pacing. Comparison between echo and peak endocardial acceleration measurements. 1:126–130.
16. Reichek N, Helak J, Plappert T, Sutton MS, Weber KT. (1983) Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results. Circulation 67:348–352.[Abstract/Free Full Text]
17. Yu CM, Fung WH, Lin H, Zhang Q , Sanderson JE, Lau CP. (2003) Predictors of left ventricular reverse remodelling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischaemic cardiomyopathy. Am J Cardiol 91:684–688.[CrossRef][ISI][Medline]
18. Naqvi TZ, Goel RK, Forrester JS, Siegel RJ. (1999) Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 34:1537–1544.[Abstract/Free Full Text]
19. Miyatake K, Yamagishi M, Tanaka N, Uematsu M, Yamazaki N, Mine Y, Sano A, Hirama M. (1995) New method for evaluating left ventricular wall motion by color-coded tissue Doppler imaging: in vitro and in vivo studies. J Am Coll Cardiol 25:717–724.[Abstract]
20. Yu CM, Wang Q , Lau CP, Tse HF, Leung SK, Lee KL, Tsang V, Ayers G. (2001) Reversible impairment of left and right ventricular systolic and diastolic function during short-lasting atrial fibrillation in patients with an implantable atrial defibrillator: a tissue Doppler imaging study. Pacing Clin Electrophysiol 24:979–988.[CrossRef][Medline]
21. Yu CM, Lin H, Zhang Q , Sanderson JE. (2003) High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart 89:54–60.[Abstract/Free Full Text]
22. Yu CM, Fung JW, Zhang Q , Chan CK, Chan YS, Lin H, Kum LC, Kong SL, Zhang Y, Sanderson JE. (2004) Tissue Doppler imaging is Superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodelling in both ischaemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation 110:66–73.[Abstract/Free Full Text]
23. Fleming AD, Xia X, McDicken WN, Sutherland GR, Fenn L. (1994) Assessment of colour Doppler tissue imaging using test-phantoms. Ultrasound Med Biol 20:937–951.[CrossRef][ISI][Medline]
24. Stellbrink C, Breithardt OA, Franke A, Sack S, Bakker P, Auricchio A, Pochet T, Salo R, Kramer A, Spinelli J. (2001) PATH-CHF (PAcing THerapies in Congestive Heart Failure) Investigators; CPI Guidant Congestive Heart Failure Research Group Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodelling in patients with congestive heart failure ventricular conduction disturbances. J Am Coll Cardiol 38:1957–1965.[Abstract/Free Full Text]
25. Kass DA, Chen CH, Talbot MW, Rochitte CE, Lima JA, Berger RD, Calkins H. (1999) Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 99:1567–1573.[Abstract/Free Full Text]
26. Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, Huth C, Schondube F, Wolfhard U, Bocker D, Krahnefeld O, Kirkels H. (2002) Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 39:2026–2033.[Abstract/Free Full Text]
27. Zhang J and McDonald KM. (1995) Bioenergetic consequences of left ventricular remodeling. Circulation 92:1011–1019.[Abstract/Free Full Text]
28. Eichhorn EJ, Heesh CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. (1994) Effect of metoprolol on myocardial function and energetics in patients with non-ischaemic dilated cardiomyopathy: a randomized double-blind, placebo-controlled study. J Am Coll Cardiol 24:1310–1320.[Abstract]
29. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, et al. (1994) Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 89:658–675.
30. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. (1997) Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia–New Zealand heart failure research collaborative group. J Am Coll Cardiol 29:1060–1066.[Abstract]
31. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94:2807–2816.[Medline]
32. Fung JW, Yu CM, Yip G, Zhang Y, Chan H, Kum CC, Sanderson JE. (2004) Variable left ventricular activation pattern in patients with heart failure and left bundle branch block. Heart 90:17–19.[Abstract/Free Full Text]
33. Auricchio A, Fantoni C, Regoli F, Carbucicchio C, Goette A, Geller C, Kloss M, Klein H. (2004) Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 109:1133–1139.[Abstract/Free Full Text]

CiteULike    Connotea    Del.icio.us    What's this?

Related articles in EHJ:

Regression of left ventricular mass and wall thickness after cardiac resynchronization therapy: proof of pathophysiological concept

Herman Mannaerts
EHJ 2006 27: 1392-1393. [Extract] [Full Text]  

This article has been cited by other articles:

				F. W. Prinzen and A. Auricchio Is echocardiographic assessment of dyssynchrony useful to select candidates for cardiac resynchronization therapy?: Echocardiography Is Not Useful Before Cardiac Resynchronization Therapy if QRS Duration Is Available Circ Cardiovasc Imaging, July 1, 2008; 1(1): 70 - 78. [Full Text] [PDF]

				A. Auricchio and F. W. Prinzen Update on the pathophysiological basics of cardiac resynchronization therapy Europace, July 1, 2008; 10(7): 797 - 800. [Abstract] [Full Text] [PDF]

				J. van Dijk, P. Knaapen, I.K. Russel, T. Hendriks, C.P. Allaart, C.C. de Cock, and O. Kamp Mechanical dyssynchrony by 3D echo correlates with acute haemodynamic response to biventricular pacing in heart failure patients Europace, January 1, 2008; 10(1): 63 - 68. [Abstract] [Full Text] [PDF]

				K. Vernooy, R. N.M. Cornelussen, X. A.A.M. Verbeek, W. Y.R. Vanagt, A. van Hunnik, M. Kuiper, T. Arts, H. J.G.M. Crijns, and F. W. Prinzen Cardiac resynchronization therapy cures dyssynchronopathy in canine left bundle-branch block hearts Eur. Heart J., September 1, 2007; 28(17): 2148 - 2155. [Abstract] [Full Text] [PDF]

				C.-M. Yu, F. Fang, Q. Zhang, G. W.K. Yip, C. M. Li, J. Y.-S. Chan, L. Wu, and J. W.-H. Fung Improvement of Atrial Function and Atrial Reverse Remodeling After Cardiac Resynchronization Therapy for Heart Failure J. Am. Coll. Cardiol., August 21, 2007; 50(8): 778 - 785. [Abstract] [Full Text] [PDF]

				F. A. McAlister, J. Ezekowitz, N. Hooton, B. Vandermeer, C. Spooner, D. M. Dryden, R. L. Page, M. A. Hlatky, and B. H. Rowe Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction: A Systematic Review JAMA, June 13, 2007; 297(22): 2502 - 2514. [Abstract] [Full Text] [PDF]

				J. D. Burkhardt and B. L. Wilkoff Interventional Electrophysiology and Cardiac Resynchronization Therapy: Delivering Electrical Therapies for Heart Failure Circulation, April 24, 2007; 115(16): 2208 - 2220. [Abstract] [Full Text] [PDF]

				J. A. Jarcho Biventricular pacing. N. Engl. J. Med., July 20, 2006; 355(3): 288 - 294. [Full Text] [PDF]

				H. Mannaerts Regression of left ventricular mass and wall thickness after cardiac resynchronization therapy: proof of pathophysiological concept Eur. Heart J., June 2, 2006; 27(12): 1392 - 1393. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 27/12/1423    most recent ehi885v2 ehi885v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in EHJ Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (9) Request Permissions Google Scholar Articles by Zhang, Q. Articles by Yu, C.-M. Search for Related Content PubMed PubMed Citation Articles by Zhang, Q. Articles by Yu, C.-M. Social Bookmarking          What's this?

Online ISSN 1522-9645 - Print ISSN 0195-668x

Copyright © 2008 European Society of Cardiology

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books